Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00116636
Recruitment Status : Completed
First Posted : June 30, 2005
Last Update Posted : May 1, 2017
Information provided by:
Therapeutic Concepts

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Actual Study Completion Date : December 2007
Kaletra® (lopinavir/ritonavir) capsules-Complete Product Information
Information for Clinical Investigators: Lopinavir (Abbott-157378) V 7.0
Kempf et al. Seville 2002
Stevens, et al. SOKRATES: Prospective Clinical Trials to Investigate the Evolution of Protease Resistance During Lopinavir/r Treatment. 2003. 1st European Drug Resistance Workshop, Luxemburg
Allavena et al. Lopinavir/ritonavir-Efavirenz (LPV/r-EFV) NRTI-sparing Regimen (BIKS study): Preliminary Efficacy and Safety Data. 42nd ICAAC, San Diego 2002, #H-169
Lauenroth-Mai & Schuler. Nuc-sparing salvage therapy: Immunological and virological response to a combination of indinavir (IDV) and lopinavir/ritonavir (LPV/r) in intensively pretreated HIV-infected patients with multiple NRTI resistance mutations. 6th IWDTHI, Glasgow 2002.
Gathe et al. Pilot Study of the Safety and Efficacy of Lopinavir/Ritonavir (LPV/r) as Single Agent Therapy in HIV-1 ARV Naïve Patients. 44th Annual ICAAC, Washington, DC 2004.
Pierone et al. Initial clinical experience with Kaletra (LPV/r) single agent therapy in HIV infection. 2002. HIV DART; Poster 076
Pierone et al. Genotypic and phenotypic resistance observations among patients with viremia with on lopinavir/ritonavir "monotherapy". 44th Annual ICAAC, Washington, DC 2004.